Request A Consultation
We will do our best to accommodate your busy schedule. Schedule and appointment today!
Low Level Laser - Pain Therapy
Our Sandyston office is now home to the state-of-the-art Erchonia FX-635 Laser!
This is major news for our office, even more so for our patients. We’ve invested our resources in order to provide our patients with some of the latest, FDA-approved technologies which are designed to extirpate pain, specifically chronic lower back pain and plantar fasciitis.
Most of us have experienced pain. According to a 2012 National Health Interview Survey, 11.2% (25.3 million people!) have experienced some sort of pain, everyday, for the past three months. Whether you have undergone surgery, thinking about surgery, or have experienced pain due to everyday wear-and-tear, unexpected accidents, etc., Cunico Health and Wellness can help you manage the pain and eliminate it through non-invasive procedures such as an Erchonia Cold, Low-Level Laser.
A new technology to effectively treat pain without harmful side effects. Low Level Laser Therapy (LLLT) or Cold Laser, is a painless, sterile, non-invasive, drug-free modality that is used for a variety of conditions such as, acute and chronic pain.
FAQ on the Erchonia FX-635 Laser
The FX 635 laser produces a low-level, or cold, output that has no thermal effect on the body’s tissue (you can’t even feel it). FDA-approved for both efficacy and safety, FX 635’s low level laser technology works by stimulating a physiological response which accelerates healing.
Yes. Erchonia submitted the results of their successful clinical trial and the laser was granted market clearance by the FDA in April 2014 for the reduction of chronic heel pain from plantar fasciitis.
There are no side effects; no pain, discomfort or recovery time of any kind. The FX 635 laser is completely non-invasive.
Erchonia received FDA clearance based on a double-blind, randomized, multi-site and placebocontrolled clinical trial. After just two FX 635 treatments a week for three weeks, patients treated with the FX 635 laser reported reduced pain on the visual analog scale at 2 weeks, 6 months and 12 months post-treatment. On average, patients went from a 68 on the VAS scale down to 8 at the 12-month mark. Those patients who received a placebo laser did a not achieve a statisticallysignificant reduction in pain at any time during the clinical trial. In order to participate in the study,
patients had to have self-reported pain of greater than 50 on VAS of 0 to 100 and be unresponsive to conservative measures.
The patient will feel no heat or any sensation from the laser.
Results vary from patient to patient but could appear after the first laser treatment.